Application of antibody-drug conjugates in the treatment of non-small cell lung cancer / 国际肿瘤学杂志
Journal of International Oncology
; (12): 296-301, 2022.
Article
in Zh
| WPRIM
| ID: wpr-930083
Responsible library:
WPRO
ABSTRACT
Antibody-drug conjugates (ADCs) have overcome the limitations of traditional chemotherapy and targeted therapy with unique advantage of antibody targeting, and made breakthrough achievements in the treatment of lung cancer. At present, the researches of ADCs in non-small cell lung cancer mainly involve HER2, HER3, TROP2, MET, CEACAM5. Many ADCs have passed rigorous clinical trials, and have shown good safety and efficacy, which provides theoretical basis for individualized treatment of lung cancer.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Journal of International Oncology
Year:
2022
Type:
Article